MANE · Veradermics, Inc
The latest filing states the doubt was alleviated.
“In accordance with Accounting Standards Update ("ASU") 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued. ... As of June 30, 2026, we had $819.9 million in cash, cash equivalents and marketable securities. We expect our existing cash, cash equivalents and marketable securities will enable the Company to meet its obligations for at least the twelve-month period from the date the financial statements are available to be issued.”View the 10-Q filed Aug 11, 2026
Price & Indicators
The closing range uses available history since Feb 4, 2026; less than a full year is stored.
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Jul 15, 2026TL;DR. Veradermics reported positive Phase 2 Study 207 results for VDPHL01 in female pattern hair loss, showing robust hair count gains and high patient-reported improvement with no cardiac safety signals, and completed enrollment in the registration-directed Phase 2/3 Study 306 with topline readout now guided to 1H27; quarterly net loss widened to $23.5M with higher opex while cash position strengthened to $819.9M, funding operations into 2030.
- + Positive Phase 2 Study 207 results showed robust hair count gains in female pattern hair loss with VDPHL01.
- + High patient-reported improvement in hair coverage supports strong efficacy profile.
- + No cardiac safety signals or treatment-related SAEs observed in female Phase 2 study.
- + Completed enrollment in 556-participant registration-directed Phase 2/3 Study 306 in females.
- + Cash position of $819.9M is expected to fund operations into 2030 through Phase 3 readouts and potential commercial launch.
- − Net loss widened to $23.5M in Q2 2026 from $15.6M in Q2 2025 on higher operating expenses.
- − R&D and G&A expenses increased significantly year-over-year as headcount and commercial readiness ramped.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MANE
this stock
Veradermics, Inc
|
$4.87B | — | — | — | 9.8% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +10.8% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.3% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +535.7% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MANE | -7.5% | +4.9% | +35.4% | -10.1% | — |
| SPY | +2.0% | +1.7% | +11.3% | +2.2% | +14.3% |
| vs SPY | -9.5% | +3.2% | +24.0% | -12.3% | — |